This study compared the effectiveness of mycophenolate mofetil (MMF) versus intravenous cyclophosphamide (IVC) for treating lupus nephritis. Over 24 weeks, MMF was found to be as effective as IVC in achieving remission, with fewer severe side effects like infections. While not blinded, MMF had a more favorable safety profile compared to IVC which had several hospitalizations due to dehydration from gastrointestinal symptoms. However, the study was limited by its short duration and not assessing long-term outcomes of remission.